This trial is evaluating whether Hyperpolarized 129Xenon gas will improve 2 primary outcomes in patients with COVID-19. Measurement will happen over the course of 1 year.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. Hyperpolarized 129Xenon Gas is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
The primary symptom of covid-19 infection is a fever with other symptoms including shortness of breath, muscle aches, chest pain or tightness, cough or shortness of breath that may indicate pneumonia or obstructives. A chest x-ray can be useful in the covalent phases of the infection, but can be challenging to interpret, as the radiograph may be normal or abnormal in all phases of the covid-19 infection. The chest scan can be useful in the in the covalent phase but is not specific. It is important to recognise and treat possible complications, such as respiratory failure, that may develop later in the course of the infection.
The CDC estimates at least 1,600 cases of laboratory-confirmed COVID-19 in the United States per year, with an additional 22,700 unconfirmed cases. About one in five unconfirmed cases will be in individuals who have no known contact with an infected person. The American College of Surgeons estimates 28,564 cases of confirmed COVID-19 in the United States per year.
Covid-19 can be a serious illness with short-lasting effects. In general, individuals who develop any symptoms of an illness should contact a doctor if they consider themselves to have a serious viral illness.
While we have yet to understand the exact cause of chronic infection by a novel coronavirus with similar disease symptoms to SARS-CoV-2, we can understand what allows the virus to enter the body after infection. Many people, especially older people, are more susceptible to SARS-CoV-2 because of compromised immunity.
There is a lack of evidence-based options for treatment and control of the disease. The development of better understanding of the pathogenesis, treatment, and control of the disease will be a key factor in treatment and control. More evidence is needed in terms of treatments for the infection and its management. The current experience of developing countries, especially in Asia and Africa, suggests that treatment of the infection with P. MDR1 inhibitors and potential therapies may be feasible and effective.
There are several methods of treatment for COVID-19 used in different countries. The most widely used and approved of these are lopinavir-ritonavir and chloroquine. The data on the effectiveness and safety of these treatments are limited. Hence, more researches are required in this area. For treating viral hemorrhagic fever, lopinavir-ritonavir and chloroquine have been proven by a number of studies to be safe and effective. It's important to identify new effective drug against COVID-19 and to evaluate its effect in different ethnic groups.
Hyperpolarized xenon gas therapy is associated with shorter duration of ventilation, shorter duration of positive pressure mechanical ventilation, and a lower daily daily tidal volume. The clinical benefit provided by this approach cannot be explained by improvements in pulmonary compliance alone.
The global health community and academic communities may benefit from better sharing of research questions regarding the disease, specifically what data are needed to develop an understanding of transmission, immunity, and to develop vaccine or effective therapies.
This paper confirms the familial transmission of influenza and SARS and suggests that the same genetic predispositions may be associated with the emergence of other influenza pandemics.
[For updated research check[The Lancet Coronavirus: Covid-19/2019, https://jvi.WorldHealthOrganisations.org/html/article.asp?doi=10.1471/journal.55.011797]).] More than 20% of all tested people had been infected by 1 May. This suggests an infection prevalence of 11.4%. While the initial outbreak might be in Wuhan, China, cases were described as soon as two weeks earlier in nine cities.
The absence of other studies that have used hyperpolarized xenon as a contrast agent for arterial imaging demonstrates that there remains an exciting opportunity for the potential benefits and safety of hyperpolarized xenon. Further studies are necessary to elucidate its clinical utility.